Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of KSI-301 versus aflibercept in treatment-naive diabetic macular edema
MOH_2021-01-06_009644Phase 3Completed
- Sponsor
- Kodiak Sciences
- Start
- Dec 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic macular edema (DME) comparing KSI-301 with aflibercept (2 arms). Primary endpoint: Mean change in best-corrected visual acuity from Day 1 to Year 1. Started Dec 2020; status: completed.
02
Drugs
tarcocimab tedromeraflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on MOH_2021-01-06_009644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-06_009644.